Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Huang

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Molecular Cancer Research : MCR|August 31, 2017
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based SubtypesLi Zhang, Kenzie D MacIsaac, Ting Zhou, et al.
Cancer Discovery|April 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersHilary E Nicholson, Douglas A Whittington, Frank J Bruzzese, et al.
Science Translational Medicine|May 26, 2017
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activationDavid P Kodack, Vasileios Askoxylakis, Gino B Ferraro, et al.
Cancer Discovery|May 15, 2015
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitorsGarrett M Frampton, Siraj M Ali, Mark Rosenzweig, et al.
Cancer Research|August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 ImmunotherapyLeanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Molecular Cancer Research : MCR|August 31, 2017
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based SubtypesLi Zhang, Kenzie D MacIsaac, Ting Zhou, et al.
Cancer Discovery|April 19, 2026
TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancersHilary E Nicholson, Douglas A Whittington, Frank J Bruzzese, et al.
Science Translational Medicine|May 26, 2017
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activationDavid P Kodack, Vasileios Askoxylakis, Gino B Ferraro, et al.
Cancer Discovery|May 15, 2015
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitorsGarrett M Frampton, Siraj M Ali, Mark Rosenzweig, et al.
Cancer Research|August 29, 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 ImmunotherapyLeanne G Ahronian, Soumyadip Sahu, Minjie Zhang, et al.
Nature|October 9, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitorsFerdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, et al.
Pageof 8